All Publications — CAMS Oxford Institute

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Immunogenicity of MVA-BN vaccine deployed as mpox prophylaxis: a prospective, single-centre, cohort study and analysis of transcriptomic predictors of response

Drennan PG. et al, (2025), The Lancet Microbe, 6, 101045 - 101045

T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccination

Chen J-L. et al, (2025), Nature Communications, 16

Unconventional human CD61 pairing with CD103 promotes TCR signaling and antigen-specific T cell cytotoxicity

Hamid MHBA. et al, (2024), Nature Immunology, 25, 834 - 846

Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells

Barnkob MB. et al, (2024), Nature Communications, 15

Engineering immunosuppressive drug-resistant armored (IDRA) SARS-CoV-2 T cells for cell therapy

Chen Q. et al, (2023), Cellular & Molecular Immunology, 20, 1300 - 1312

PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer

Woodcock VK. et al, (2023), BJUI Compass, 4, 322 - 330

Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination

Yin Z. et al, (2023), Cell Reports, 42, 112470 - 112470

Recombinant single-cycle influenza virus with exchangeable pseudotypes allows repeated immunization to augment anti-tumour immunity with immune checkpoint inhibitors

Kandasamy M. et al, (2023), eLife, 12

Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell–mediated toxicity against glioblastoma

Ma R. et al, (2022), Neuro-Oncology, 24, 2093 - 2106

An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease

Peng Y. et al, (2022), Nature Immunology, 23, 50 - 61

Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1157-165 tumor-specific peptide

Shenderov E. et al, (2021), Journal for ImmunoTherapy of Cancer, 9, e002544 - e002544

Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation

Crump NT. et al, (2021), Cell Reports, 35, 109101 - 109101

PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses

Dölen Y. et al, (2021), Frontiers in Immunology, 12

Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells

Prota G. et al, (2020), Cancer Immunology Research, 8, 685 - 697

Self-Maintaining CD103+ Cancer-Specific T Cells Are Highly Energetic with Rapid Cytotoxic and Effector Responses

Abd Hamid M. et al, (2020), Cancer Immunology Research, 8, 203 - 216

Load More